1	Geospatial distribution of Hepatitis B pre-	vention services in Wakiso District,
2	Central Ug	anda
3	Tonny Ssekamatte <sup>1</sup> , John Bosco Isunju <sup>1</sup> , Aisha Nal	ugya <sup>1</sup> , Solomon Tsebeni Wafula <sup>1</sup> , Rebecca
4	Nuwematsiko <sup>1</sup> , Nakalembe Doreen <sup>1</sup> , Winnifred	K. Kansiime <sup>1</sup> , Muyanga Naume <sup>1</sup> , Joana
5	Nakiggala <sup>1</sup> , Justine N. Bukenya <sup>2</sup> , Richard K. Muga	umbe <sup>1</sup>
6	Affiliations	
7	<sup>1</sup> Department of Disease Control and Environmenta	l Health, School of Public Health, College
8	of Health Science, Makerere University. P.O Box 7	7072, Kampala, Uganda
9		
10	<sup>2</sup> Department of Community Health and Behavioura	al Sciences, School of Public Health,
11	College of Health Science, Makerere University. P	.O Box 7072, Kampala, Uganda
12		
13	Correspondence addressed to;	
14	Tonny Ssekamatte	
15	Email: ssekamattet.toca@gmail.com; tssekamatte@	musph.ac.ug
16	Mobile: +256 782 381 484	
17		
18	Contact details	
19	John Bosco Isunju, PhD	isunju@musph.ac.ug
20	Aisha Nalugya, BEHS	aishanalugya18@gmail.com
21	Solomon Tsebeni Wafula, MSc.	swafula@musph.ac.ug
22	Rebecca Nuwematsiko, MPH	rnuwematsiko@musph.ac.ug
23	Doreen Nakalembe, BES	nakadora26@gmail.com
24	NOTE: This preprint reports new research that has not been certified by $Winnie\ K.\ Kanslime,\ MSc.$	peer review and should not be used to guide clinical practice. <u>winniekanstime@musph.ac.ug</u>

25	Muyanga Naume, MPH	mngnaomi@gmail.com
26	Joana Nakiggala, MPH	jnakiggala88@gmail.com
27	Justine N. Bukenya, PhD	Jbukenya@musph.ac.ug
28	Richard K. Mugambe, PhD	rmugambe@musph.ac.ug
29		
30		

#### 31 Abstract

#### 32 Introduction

Despite global and national efforts in place for the prevention and control of Hepatitis B, there
remains a gap in access to hepatitis B prevention services such as testing and vaccination.
Nonetheless, there is limited evidence of the geospatial distribution of Hepatitis B services.
This study established the geospatial distribution of HBV vaccination services in Wakiso
District, Uganda.

#### 38 Materials and methods

A cross-sectional quantitative descriptive study was conducted among 55 healthcare facilities including 6 hospitals, and 49 primary care facilities in Wakiso district. Data were collected using the KoboCollect application. Quantitative data were analysed using STATA 14.0. A chisquare test was performed to establish the relationship between healthcare facility characteristics and the availability of hepatitis B services. ArcGIS (version 10.1) was used for analysis of geospatial data.

#### 45 **Results**

The hepatitis B vaccine was available in only 27.3 % (15) of the facilities, and 60% (33) had 46 testing services. Receipt of the hepatitis B vaccine doses in the last 12 months was associated 47 with the level of healthcare facility (p=≤0.001) and location (p=0.030). Availability of the 48 Hepatitis B vaccines at the time of the survey was associated with the level of healthcare facility 49 50 (p=0.002) and location (p=0.010). Availability of hepatitis B testing services was associated with level of healthcare facility (p=0.031), ownership ( $p\le 0.001$ ) and location (p=0.010). 51 Healthcare facilities offering vaccination and testing services were mostly in urban healthcare 52 facilities, and close to Kampala, Uganda's capital. 53

#### 54 Conclusion

- Hepatitis B services were sub-optimal across all healthcare facility levels, locations, and
  ownership. The majority of the hepatitis B prevention services were provided in urban settings,
  close to major towns, municipalities, and the city. This calls a extension of hepatitis B
  prevention services to rural, public and PNFP healthcare facilities.
- 60 Key words
- 61 Geospatial distribution, hepatitis B testing, hepatitis B vaccination, infection prevention and
- 62 control, Uganda

63

# 64 Introduction

Hepatitis B virus (HBV) infection remains a serious global public health concern, affecting 65 over 257 million people (1, 2). Low-and-middle income countries (LMICs) bare the greatest 66 burden of HBV infection, accounting for almost all (96%) individuals living with the disease 67 (1). The incidence of HBV infection is 9.2 times higher in LMICs than high-income countries 68 (1). The WHO African region has the second highest prevalence of HBV infection (6.1%) 69 while America has the lowest (0.7%) (1). The prevalence of HBV infection in Uganda is 4.1% 70 among adults and 0.6% among children. It is highest in the mid-north (4.6%) and lowest in the 71 72 south-western region (0.8%) of the country (3). Despite the high public health burden of HBV infection in LMICs including Uganda, access to testing, vaccination, treatment and 73 management services remains suboptimal (1). Nonetheless, a large burden of chronic infections 74 requires increased access to testing and treatment services (4, 5). 75

76 HBV is an infection of the liver, transmitted through contact with blood or other body fluids of an infected person. The risk of chronic HBV infection and co-infection is high among under-77 78 fives, health care providers, and people living with HIV/AIDS respectively (1, 6). A large proportion of HBV cases are carriers who may remain asymptomatic for a long time, thus 79 increasing their risk of liver cirrhosis, hepatocellular carcinoma and early death (1). Access to 80 81 vaccination and screening/testing is critical in the prevention and management, and elimination of HBV infection by 2030 (1, 7). Availability of testing services is key in the diagnosis of 82 chronic HBV, and consequently linkage of patients to appropriate care and treatment, which 83 eventually delays progression of liver disease (4, 5, 7). Additionally, availability of testing 84 services provides an avenue for counselling on risky behaviours, provision of prevention 85 commodities such as sterile needles and syringes, and vaccination (4, 5). Vaccination reduces 86 the risk of HBV infection, and co-infection with Hepatitis D virus, which is known to 87 aggreveate the outcome of HBV infection (1, 8, 9). 88

Although evidence on global and regional coverage of hepatitis B vaccination among adults is scarce, high-income countries with vaccination data reveal low rates (10). Limited access to testing and vaccination services among adults born before the HBV vaccination era increases their risk of infection and death (1, 5). Available data on vaccination coverage among groups at an elevated risk of the HBV infection in low-income countries reveal suboptimal rates (11-14).

There have been various strategies at global, regional and national level aimed at reducing 95 disparities in access to hepatitis B prevention, care and treatment services (15). In 2016, the 96 World Health Organisation (WHO) developed a global health sector strategy on viral hepatitis 97 98 (2016–2021) which envisioned a world where viral hepatitis transmission is halted and 99 everyone living with viral hepatitis has access to safe, affordable and effective prevention, care and treatment services (1, 7). In response to the WHO recommendations and targets, the 100 101 Ugandan Ministry of Health (MoH) called for increment in massive community awareness of HBV, screening and vaccination of all susceptible persons, improving the supply chain for 102 103 HBV related commodities and supplies, attachment of patients to treatment care, and support programs, integration of services and resource mobilisation and equipping Healthcare 104 105 practitioners (HCPs) with adequate knowledge on the management of HBV infection (MoH, 106 2016b). More so, the government of Uganda allocated US\$2,847,000 in 2016 towards the procurement of vaccines, laboratory reagents, and anti-viral drugs for the prevention and 107 treatment of Hepatitis B (16). 108

Hepatitis B vaccination in Uganda was introduced in 2002, implying that adults born before that year missed out on the routine vaccination given to newborns at 6, 10 and 14 weeks of age through the expanded programme on immunisation (17). Despite efforts to improve access to hepatitis B prevention, care and treatment services, their distribution in Wakiso district is unknown. (17). Our study sought to undertake a geospatial and descriptive analysis of hepatitis

B prevention services, vaccine doses, testing kits and trained personnel, as well as understand
the relationship between healthcare facility (HCF) characteristics and availability of hepatitis
B prevention services and supplies.

#### 117 Materials and methods

# 118 Study setting

This study was conducted in Wakiso district, Central Uganda in July 2018. Wakiso District is 119 located in the Central Region of Uganda and partly encircles Kampala, Uganda's capital. 120 Wakiso District boarders Mpigi, Luweero, Nakaseke and Mityana Districts in the North; 121 Mukono in the East and Kalangala district to the South. It has a total of 7 health sub-districts 122 namely; Busiro east, Busiro north, Busiro south, Kyadondo east, Kyadondo north, Kyadondo 123 south, and Entebbe municipality. In 2014, Wakiso was estimated to have a population of 124 1,997,418 people, of which 1,048,383 were females (18). The district has a total of 589 HCFs, 125 among which 72 are owned and managed by the government (public), 477 are privately owned 126 (private for-profit) and 40 are private not-for-profit (19). Based on the level of the HCFs, 234 127 are private clinics, 153 are health centre IIs, 165 are health centre IIIs, 19 are health centre IVs, 128 129 14 are hospitals, and 3 are specialised clinics. Wakiso is also home to the Entebbe regional referral hospital (19). 130

131

In terms of management of health services in Uganda, healthcare services in the district are overseen by the District Health Officer who is supported by two assistants. The district is further divided into health sub-districts, which are overseen by a management committee. The functions of the committee include monitoring the general administration of the health Subdistrict on behalf of the district local council and MoH. Each of these committees has a health sub-district manager, often an in-charge at a health centre IV, whose role involves coordination,

planning, and budgeting for medical supplies and infrastructure, budget execution, andsupervision of lower-level HCFs such as health centre IIIs and IIs (20).

140

#### 141 Study design and data collection tools

A cross-sectional study design was used to collect quantitative data from each of the study 142 HCFs. A structured questionnaire was used to obtain data from the HCF managers. Where 143 observations were required, questions prompting the researcher to make such observations 144 were embedded in the data collection tool. The structured questionnaire was developed by the 145 146 lead investigators (TS, JBI, and RKM) after a thorough review of literature pertaining provision of vaccination services (21, 22), and the service availability and readiness assessment (SARA) 147 framework. The SARA framework is designed as a systematic survey to generate a set of core 148 indicators of services, which can be used to measure progress in health system strengthening 149 over time (23, 24). The study specifically focused on service availability, which is defined as 150 the physical presence of the delivery of services, encompassing the health infrastructure, core 151 health personnel, and service utilization (23, 24). The SARA is useful in the identification of 152 153 the proportion of HCFs offering a particular intervention/service-in this case hepatitis B vaccination services, and whether the HCFs offering the service (HBV services) have the 154 minimum standard in terms of equipment, trained staff and guidelines, diagnostic capacity, and 155 medicines to provide an adequate level of service (service readiness) (23, 25). The data 156 collection tool was reviewed and evaluated for face and internal validity by experts in viral 157 hepatitis research, based at the Makerere University College of Health Sciences. 158

# 159 Study variables

160 The validated tool captured data on the HCF characteristics such as level (categorised as 161 hospital, health centre IVs, and IIIs), ownership (Private for-profit (PFP), Private not-for-profit 162 (PNFP), and Public/government-owned), and location (rural/urban). Urban HCFs included those administratively located in municipalities or town councils while rural HCFs were those located in a sub-county (26). Data were collected on the availability of vaccination and testing services, trained personnel, and vaccination storage equipment such as refrigerators. In addition, observations were made to ascertain the availability of hepatitis B testing kits, vaccine doses, infection prevention and control promotion materials, and disposal of medical wastes such as sharps.

# 169 Sample size, sampling procedure, data collection procedures, and data analysis

A total of 55 HCFs were surveyed. The sampling of the HCFs in the current study was 170 purposive and has been detailed in our earlier publications (11, 27). Briefly, based on the 171 national health facility inventory (19), we purposively selected 6 hospitals, 16 health centre 172 IVs and 33 IIIs because these provided high-risk medical interventions such as blood 173 transfusions, delivering higher numbers of mothers, and other surgical procedures that can 174 elevate the risk of transmission of HBV (27, 28). Upon selection of the HCFs, data were 175 collected using the Kobo Collect mobile application which was installed on Android-enabled 176 mobile phones and tablets, and preloaded with the electronic version of the questionnaire. 177 Research Assistants were required to upload the data onto a cloud server daily to avoid any risk 178 of losing it. Upon completion of the survey, data were downloaded in the MS EXCEL format, 179 checked for consistency, and cleaned. Afterwards, data were exported to STATA version 14.0 180 for analysis. Cross tabulations based on the level of the HCF, ownership, and location were 181 done and are presented in the current paper. The Chi square ( $\chi^2$ ) test was performed to establish 182 the relationship between HCF characteristics and availability of hepatitis B related services and 183 supplies. 184




Figure 1: Map of Wakiso district showing the distribution of sampled healthcare facilities by ownership status

Figure 2: Map of Wakiso district showing the distribution of sampled healthcare facilities by location

#### **186** Geospatial distribution of prevention services

185

187 The digital data collection tool which was used to gather data from HCFs also picked Geographical Positioning Systems (GPS) coordinates, i.e., northings and eastings. Location 188 data were stored on the cloud server hosted by Kobo collect, together with attribute data about 189 the HCFs. The data set was later downloaded as an excel file, checked for inconsistencies, and 190 cleared of any errors. The data file was then saved as a comma delimited text file and imported 191 192 as a layer into a GIS environment using ArcGIS (version 10.1). From the imported layer, a shapefile of point plots and corresponding attribute tables were generated. The point plots were 193 overlaid onto administrative boundaries of Wakiso district and its environs, obtained from the 194 Ugandan Bureau of Statistics (UBOS). Subsequently, shapefiles for different variables were 195 generated depending on the research questions that needed explicit representation. Maps 196 showing the geospatial distribution of different attributes such as availability of HBV, and 197 198 routine vaccination schedule for health workers were generated and exported as a jpeg.

#### 199 Quality control and quality assurance measures

Data were collected by 6 Research Assistants who were supervised by one of the lead
investigators (TS). Before data collection, Research Assistants underwent a four days' training

to familiarise themselves with the data collection protocol. As part of the training, the data collection tools were pretested at two primary HCFs in peri-urban areas of Kampala City. The pre-test HCFs had comparable characteristics as those in the study district. These characteristics included conducting high-risk medical interventions such as conducting high volume deliveries, which increases occupational exposure to viral hepatitis.

#### 207 Ethics statement

The study was approved by the Makerere University School of Public Health Higher Degrees Research and Ethics Committee. Administrative clearance was sought from the Wakiso district Local government and the management of the participating HCFs. Written informed consent was obtained from the study respondents before interviews or observations could happen. All informed consent discussions were done in English since all health workers were conversant with the language.

# 214 **Results**

# 215 Background characteristics of health facilities

Out of the 55 facilities visited, most 61.8% (34) were health centres IIIs and 47.3% (26) were privately owned. Most of the HCFs visited were located in the urban setting 65.4% (36/55) and Busiro North sub-district had the highest number 29.1% (16/55) of the facilities visited (Table 1).

Variables	Category	Frequency (N=55)	Percentage (%)
Level of health	Health Centre III	34	61.8
facility	Health Centre IV	17	30.9
	Hospital	04	7.3
Health facility	Public	23	41.8
Ownership	Private	26	47.3
	Private-not-for-profit	06	10.9
Location of the	Urban	36	65.4
facility	Rural	19	34.6
Name of the Health	Busiro North	16	29.1
sub-district	Busiro East	7	12.7
	Busiro south	5	9.1


220 Table 1: Background characteristics of study healthcare facilities

Kyadondo North	10	18.2
Kyadondo south	06	10.9
Kyadondo East	10	18.2
Entebbe municipality	01	1.8

# 221

# Availability and distribution of Hepatitis B vaccine doses, testing kits and trained personnel


Only 29% (16) of the 55 HCFs reported having received hepatitis B vaccine doses in the last 224 12 months. At the time of the study, the hepatitis B vaccine was available in only 27.3 % 225 (15/55) of the facilities; mostly in HC IVs 52.9% (9/17) and lowest in HC IIIs 11.8% (4/34). 226 More urban HCFs, 93.3% (14/15) had hepatitis B vaccine available at the time of the study 227 than rural ones 6.7% (1/14). Most HCFs 60.0% (33/55) had testing kits among which all 228 229 hospitals and PNFP facilities had hepatitis B testing kits at their facilities. More urban HCFs, 230 72.2% (26/36) had testing kits than rural ones 36.8% (7/19). Although 30.9% (17/55) of the HCFs had personnel trained on Hepatitis B management; only 1 hospital 25.0% (1/4) and 3 231 13.0% (3/23) public facilities had their personnel trained on hepatitis B management. Infection 232 control promotion materials were found in 89.1% (49/55) of the facilities; 91.2% (31/34) in 233 HC IIIs, 82.4% (14/17) in HCIV and all hospitals. Nearly three guarters 65.6% (36/55) of the 234 235 HCFs had post-exposure prophylaxis (PEP) guidelines in case of accidental injuries; this was lowest in public facilities 65.2% (15/23). Almost all facilities 96.4% (53/55) had handwashing 236 facilities (Table2). 237



238

**Figure 3:** A map of Wakiso district showing the distribution of healthcare facilities that

240 offer hepatitis B testing services




242

# 246 Availability and distribution of routine vaccination services for healthcare providers

Only 29.1% (16/55) of the HCFs surveyed had a routine vaccination schedule for the health care providers. The majority of the HCFs that had a routine vaccination schedule were clustered in the same area, with just a few dispersed outwards (Figure 1). The majority of the HCFs were also located just adjacent to Kampala, Uganda's Capital with more than half, 62.5% (10/16) in the urban areas and over a third, 37.5% (6/16) in the rural areas.

<sup>Figure 4: A map showing healthcare facilities with the hepatitis B vaccine in Wakiso
district, Uganda</sup> 

<sup>245</sup> 



252

Figure 5: A map of Wakiso district showing healthcare facilities with a routine vaccination
schedule (as either statatic or outreach) for healthcare providers and other high-risk groups

# Relationship between healthcare facility characteristics and availability of hepatitis B prevention services and supplies

There was a statistically significant association between level of HCF and receiving hepatitis B vaccine doses in the last 12 months ( $p=\leq 0.001$ ), having Hepatitis B vaccines at the time of the survey (p=0.002), availability of hepatitis B testing services (p=0.031), having hepatitis B testing kits in stock (p=0.013), having reminders and/or job aids that promote the reduction and use of injections, safe administration of injections, or safe disposal of used injection equipment available at this facility (p=0.003) and having color-coded waste bins to promote safe waste management (p=0.043) (Table 2).

There was a statistically significant association between ownership of the HCF and availability of guidelines to follow in case healthcare providers are exposed to the hepatitis B infection ( $p \le 0.001$ ), availability of hepatitis B testing services ( $p \le 0.001$ ), availability of hepatitis B testing kits ( $p \le 0.001$ ), poor management of infectious waste (p = 0.007), and having someone trained in the management of hepatitis B (p = 0.049).

- The location of HCF was associated with receiving hepatitis B vaccine doses in the last 12 months (p=0.030), and availability of Hepatitis B vaccines (p=0.010), testing services (p=0.010) and Hepatitis B testing kits (p=0.004). The location of the HCF was also associated with availability of guidelines to follow in case healthcare providers are exposed to the
- hepatitis B infection (p=0.040) and presence of staff trained in hepatitis B testing (p=0.050).

275

276	able 2: Availability of hepatitis B prevention services in Wakiso district, Central Uganda, stratified by level of the healthcare facility,	
277	vnership, and location	

Indicator	(N=55) (%)	Health fac	ility level N (	%)	χ <sup>2</sup> p-								χ <sup>2</sup> p-	Location 1	Location N (%)	
		HCIII (N = 34)	HCIV (N = 17)	Hospital (N = 4)	value	Private (N = 26)	PNFP (N = 6)	Public (N = 23)	value	Rural (N = 19)	Urban (N = 36)	_ p-value				
HCF received Hep B vaccine doses in the last 12 months	16 (29.1)	03 (8.8)	10 (58.8)	03 (75.0)	≤0.001	10 (38.5)	02 (33.3)	4 (17.4)	0.261	2 (10.5)	14 (38.9)	0.030				
HCF has functional refrigerators for storing Hepatitis B vaccines	49 (89.1)	28 (82.4)	17 (100)	04 (100)	0.125	23 (88.5)	04 (66.7)	22 (95.7)	0.127	16 (84.2)	33 (91.7)	0.399				
HCF has cold chain technicians	19 (34.6)	08 (23.5)	09 (52.9)	02 (50.0)	0.052	09 (34.6)	02 (33.3)	08 (34.8)	0.998	04 (21.1)	15 (41.7)	0.126				
Cold chain technician (s) at the HCF were trained in temperature monitoring	14 (25.4)	07 (20.5)	06 (35.2)	01 (25.0)	0.502	07 (26.9)	02 (33.3)	05 (21.7)	0.520	04 (21.1)	10 (27.7)	0.179				
HCF had Hepatitis B vaccines at the time of the survey	15 (27.3)	04 (11.8)	09 (52.9)	02 (50.0)	0.002	10 (38.5)	02 (33.3)	03 (13.0)	0.129	01 (5.3)	14 (38.9)	0.010				
HCF has guidelines to follow in case healthcare providers are exposed to the hepatitis B infection	25 (45.6)	14 (41.2)	08 (47.1)	03 (75.0)	0.432	17 (65.4)	06 (100)	02 (8.7)	≤0.001	05 (26.3)	20 (55.6)	0.040				
Hepatitis B testing services are available at the HCF	33 (60.0)	16 (47.1)	13 (76.5)	04 (100)	0.031	23 (88.5)	06 (100)	04 (17.4)	≤0.001	07 (36.8)	26 (72.2)	0.010				
HCF has Hepatitis B testing kits in stock at the time of the survey	29 (52.7)	13 (38.2)	12 (70.6)	04 (100)	0.013	21 (80.8)	05 (83.3)	03 (13.0)	≤0.001	05 (26.3)	24 (66.7)	0.004				
HCF has a routine vaccination schedule for health care providers and other target groups	16 (29.1)	08 (23.5)	05 (29.4)	03 (75.0)	0.101	07 (26.9)	02 (33.3)	07 (30.4)	0.936	06 (31.6)	10 (27.8)	0.768				
HCF has any infection prevention and control promotion materials	49 (89.1)	31 (91.2)	14 (82.4)	04 (100)	0.488	25 (96.2)	05 (83.3)	19 (82.6)	0.282	16 (84.2)	33 (91.7)	0.399				
HCF has reminders and/or job aids posted that promote reducing the use of injections, safe administration of injections, or safe disposal of used injection equipment available at this facility	44 (80.0)	31 (91.2)	10 (58.8)	03 (75.0)	0.003	21 (80.8)	06 (100)	17 (73.9)	0.360	17 (89.5)	27(75.0)	0.202				

16 (29.1)	08 (23.5)	07 (41.2)	01 (25.0)	0.418	08 (30.8)	02 (33.3)	06 (26.1)	0.910	06 (31.6)	10 (27.8)	0.768
48 (87.3)	32 (94.1)	12 (70.6)	04 (100)	0.043	22 (84.6)	06 (100)	20 (89.6)	0.594	18 (94.7)	30 (83.3)	0.228
24 (43.6)	12 (35.3)	10 (58.8)	02 (50.0)	0.270	09 (34.6)	0 (0.0)	15 (65.2)	0.007	09 (47.4)	15 (41.7)	0.685
43 (78.2)	25 (73.5)	14 (82.4)	04 (100)	0.423	22 (84.6)	06 (100)	15 (65.2)	0.100	12 (63.2)	31 (86.1)	0.050
17 (30.9)	09 (26.5)	07 (41.2)	01 (25.0)	0.544	11 (42.3)	03 (50.0)	03 (13.0)	0.049	05 (26.3)	12 (33.3)	0.592
20 (36.4)	12 (35.3)	05 (29.4)	03 (75.0)	0.229	07 (26.9)	04 (66.7)	09 (39.1)	0.177	05 (26.3)	15 (41.7)	0.260
36 (65.6)	23 (67.7)	09 (52.9)	04 (100)	0.186	16 (61.5)	05 (83.3)	15 (65.2)	0.599	13 (68.4)	23 (63.9)	0.737
46 (83.6)	30 (88.2)	12 (70.5)	04 (100)	0.098	26 (100)	06 (100)	14 (60.8)	0.236	15 (78.9)	31 (86.1)	295
	48 (87.3) 24 (43.6) 43 (78.2) 17 (30.9) 20 (36.4) 36 (65.6)	48 (87.3)       32 (94.1)         24 (43.6)       12 (35.3)         43 (78.2)       25 (73.5)         17 (30.9)       09 (26.5)         20 (36.4)       12 (35.3)         36 (65.6)       23 (67.7)	48 (87.3)       32 (94.1)       12 (70.6)         24 (43.6)       12 (35.3)       10 (58.8)         43 (78.2)       25 (73.5)       14 (82.4)         17 (30.9)       09 (26.5)       07 (41.2)         20 (36.4)       12 (35.3)       05 (29.4)         36 (65.6)       23 (67.7)       09 (52.9)	48 (87.3)       32 (94.1)       12 (70.6)       04 (100)         24 (43.6)       12 (35.3)       10 (58.8)       02 (50.0)         43 (78.2)       25 (73.5)       14 (82.4)       04 (100)         17 (30.9)       09 (26.5)       07 (41.2)       01 (25.0)         20 (36.4)       12 (35.3)       05 (29.4)       03 (75.0)         36 (65.6)       23 (67.7)       09 (52.9)       04 (100)	48 (87.3)       32 (94.1)       12 (70.6)       04 (100)       0.043         24 (43.6)       12 (35.3)       10 (58.8)       02 (50.0)       0.270         43 (78.2)       25 (73.5)       14 (82.4)       04 (100)       0.423         17 (30.9)       09 (26.5)       07 (41.2)       01 (25.0)       0.544         20 (36.4)       12 (35.3)       05 (29.4)       03 (75.0)       0.229         36 (65.6)       23 (67.7)       09 (52.9)       04 (100)       0.186	48 (87.3)       32 (94.1)       12 (70.6)       04 (100)       0.043       22 (84.6)         24 (43.6)       12 (35.3)       10 (58.8)       02 (50.0)       0.270       09 (34.6)         43 (78.2)       25 (73.5)       14 (82.4)       04 (100)       0.423       22 (84.6)         17 (30.9)       09 (26.5)       07 (41.2)       01 (25.0)       0.544       11 (42.3)         20 (36.4)       12 (35.3)       05 (29.4)       03 (75.0)       0.229       07 (26.9)         36 (65.6)       23 (67.7)       09 (52.9)       04 (100)       0.186       16 (61.5)	48 (87.3)       32 (94.1)       12 (70.6)       04 (100)       0.043       22 (84.6)       06 (100)         24 (43.6)       12 (35.3)       10 (58.8)       02 (50.0)       0.270       09 (34.6)       0 (0.0)         43 (78.2)       25 (73.5)       14 (82.4)       04 (100)       0.423       22 (84.6)       06 (100)         17 (30.9)       09 (26.5)       07 (41.2)       01 (25.0)       0.544       11 (42.3)       03 (50.0)         20 (36.4)       12 (35.3)       05 (29.4)       03 (75.0)       0.229       07 (26.9)       04 (66.7)         36 (65.6)       23 (67.7)       09 (52.9)       04 (100)       0.186       16 (61.5)       05 (83.3)	48 (87.3)       32 (94.1)       12 (70.6)       04 (100)       0.043       22 (84.6)       06 (100)       20 (89.6)         24 (43.6)       12 (35.3)       10 (58.8)       02 (50.0)       0.270       09 (34.6)       0 (0.0)       15 (65.2)         43 (78.2)       25 (73.5)       14 (82.4)       04 (100)       0.423       22 (84.6)       06 (100)       15 (65.2)         17 (30.9)       09 (26.5)       07 (41.2)       01 (25.0)       0.544       11 (42.3)       03 (50.0)       03 (13.0)         20 (36.4)       12 (35.3)       05 (29.4)       03 (75.0)       0.229       07 (26.9)       04 (66.7)       09 (39.1)         36 (65.6)       23 (67.7)       09 (52.9)       04 (100)       0.186       16 (61.5)       05 (83.3)       15 (65.2)	48 (87.3)       32 (94.1)       12 (70.6)       04 (100) <b>0.043</b> 22 (84.6)       06 (100)       20 (89.6)       0.594         24 (43.6)       12 (35.3)       10 (58.8)       02 (50.0)       0.270       09 (34.6)       0 (0.0)       15 (65.2) <b>0.007</b> 43 (78.2)       25 (73.5)       14 (82.4)       04 (100)       0.423       22 (84.6)       06 (100)       15 (65.2)       0.100         17 (30.9)       09 (26.5)       07 (41.2)       01 (25.0)       0.544       11 (42.3)       03 (50.0)       03 (13.0) <b>0.049</b> 20 (36.4)       12 (35.3)       05 (29.4)       03 (75.0)       0.229       07 (26.9)       04 (66.7)       09 (39.1)       0.177         36 (65.6)       23 (67.7)       09 (52.9)       04 (100)       0.186       16 (61.5)       05 (83.3)       15 (65.2)       0.599	48 (87.3)       32 (94.1)       12 (70.6)       04 (100)       0.043       22 (84.6)       06 (100)       20 (89.6)       0.594       18 (94.7)         24 (43.6)       12 (35.3)       10 (58.8)       02 (50.0)       0.270       09 (34.6)       0 (0.0)       15 (65.2)       0.007       09 (47.4)         43 (78.2)       25 (73.5)       14 (82.4)       04 (100)       0.423       22 (84.6)       06 (100)       15 (65.2)       0.100       12 (63.2)         17 (30.9)       09 (26.5)       07 (41.2)       01 (25.0)       0.544       11 (42.3)       03 (50.0)       03 (13.0)       0.049       05 (26.3)         20 (36.4)       12 (35.3)       05 (29.4)       03 (75.0)       0.229       07 (26.9)       04 (66.7)       09 (39.1)       0.177       05 (26.3)         36 (65.6)       23 (67.7)       09 (52.9)       04 (100)       0.186       16 (61.5)       05 (83.3)       15 (65.2)       0.599       13 (68.4)	48 (87.3)       32 (94.1)       12 (70.6)       04 (100)       0.043       22 (84.6)       06 (100)       20 (89.6)       0.594       18 (94.7)       30 (83.3)         24 (43.6)       12 (35.3)       10 (58.8)       02 (50.0)       0.270       09 (34.6)       0 (0.0)       15 (65.2)       0.007       09 (47.4)       15 (41.7)         43 (78.2)       25 (73.5)       14 (82.4)       04 (100)       0.423       22 (84.6)       06 (100)       15 (65.2)       0.100       12 (63.2)       31 (86.1)         17 (30.9)       09 (26.5)       07 (41.2)       01 (25.0)       0.544       11 (42.3)       03 (50.0)       03 (13.0)       0.049       05 (26.3)       12 (33.3)         20 (36.4)       12 (35.3)       05 (29.4)       03 (75.0)       0.229       07 (26.9)       04 (66.7)       09 (39.1)       0.177       05 (26.3)       15 (41.7)         36 (65.6)       23 (67.7)       09 (52.9)       04 (100)       0.186       16 (61.5)       05 (83.3)       15 (65.2)       0.599       13 (68.4)       23 (63.9)

#### 286 Discussion

287 The main aim of this study was to assess the availability and geospatial distribution of Hepatitis B prevention services in Wakiso District, Central Uganda. This is important since is unmasks 288 variation in service availability across a geographic space. Our analysis found that only 29% 289 290 of the HCFs had hepatisis B vaccine supplies in the last 12 months, but the vaccine was available in only 27.3 % of the HCFs at the time of the survey. We established that less than 291 half of the HCFs had infection prevention and control (IPC) guidelines to follow when exposed 292 to HBV infections, and only two-thirds of the HCFs had PEP guidelines in case of injuries. 293 Geospatial analysis indicated that the majority of the HCFs offering routine HBV vaccination 294 were clustered in the same area, with just a few dispersed outwards. Hepatitis B vaccination 295 and testing services were mainly offered by health centre IVs and hospitals. 296

Analysis of the geospatial distribution of hepatitis B prevention services such as vaccination, 297 screening, and testing, revealed that HCFs offering such services conformed to a nucleated 298 299 pattern. HCFs were located close to each other. Many of these HCFs were located close to Kampala, Uganda's capital, and in municipalities and major town councils. The location or 300 proximity of HCFs providing Hepatitis B prevention services to the more urbanised areas is 301 302 not surprising. Urbanised areas are more likely to have a higher demand for services compared to the less urbanised or rural settings. There is also evidence that urban dwellers are more likely 303 to be knowledgeable about their health, and thus can demand services. However, this has 304 implications for hepatitis B prevention. It is known that rural dwellers in Uganda have lower 305 incomes compared to urban dwellers (29, 30). Therefore, the unequal distribution of hepatitis 306 307 B prevention services is likely to limit their uptake.

308 Our study revealed that only 29% of the HCFs reported having hepatitis B vaccine doses in 309 stock in the last 12 months. Our findings indicate that less than a third of the HCFs had hepatitis

B vaccines in stock during the study period (2019). The low proportion of HCFs with hepatitis 310 B vaccine doses in stock during the study period may have been attributed to the low prevalence 311 of the disease in the region. The central region, where Wakiso district is located had a lower 312 prevalence (1.6%) of hepatitis B compared to other regions (4.6% in mid-north, 3.8% in West 313 Nile, 4.4% in northeast among other regions) (31, 32). Due to the low prevalence of hepatitis 314 B in the central region, Wakiso district was in 2015 not prioritised by the Ugandan Ministry of 315 316 Health for mass hepatitis B prevention services including screening, vaccination of adults, and testing (32). The low prevalence and consequently low prioritisation of hepatitis B prevention 317 318 services by the Ugandan Ministry of Health may have driven the availability and distribution of hepatitis B services in HCFs in Wakiso district. Besides, the low demand for hepatitis B 319 prevention services, which resulted from limited knowledge and a negative attitude towards 320 321 hepatitis B prevention among healthcare providers in Wakiso district, as earlier reported by 322 Ssekamatte, Isunju (27) could also explain the limited coverage in HCFs. The study reported that 42.2% of healthcare providers exhibited poor knowledge of HBV infection transmission 323 and prevention, 41.8% had a negative attitude while 41.5% exhibited poor hepatitis B 324 prevention practices. There is evidence that unfavourable knowledge, attitude, and practices 325 can affect the demand and supply of healthcare services (33). 326

327 A higher proportion of PNFP and private HCFs had hepatitis B prevention services such as screening and testing compared to the public HCFs. This is not surprising given the fact that 328 procurement of the vaccine greatly depended on the demand, and that the vaccine was paid for 329 by the clients. Therefore, the provision of hepatitis B vaccination services such as testing and 330 vaccination was seen as a business from which PNFP and private HCFs would make profits. 331 332 There is evidence of HCFs providing services only if they can make a profit (34). The low proportion of public HCFs reporting having hepatitis B vaccines in stock in the last 12 months 333 could be attributed to the fact that Wakiso district was not in a high-burden region, and thus, 334

not prioritised. The Ugandan Ministry of Health rolled out free vaccinations in the country
starting with regions of high prevalence that did not include Wakiso district. Thus
public/government HCFs in low burden areas did not have the vaccine readily available (32).

Less than half of the HCFs in our study setting had guidelines patients and healthcare providers could follow when exposed to the hepatitis B virus. In addition, about two-thirds of the HCFs had PEP guidelines in case of injuries. The low proportion of HCFs with infection prevention and control guidelines could have been due to the limited investment in hepatitis B prevention and control to support development and distributribution of guidelines, policies and standards to HCFs. Limited funding is widely reported to impact the provision of healthcare services, and the development and implementation of guidelines and policies (35).

Less than a third of the study HCF held continuing medical education sessions(CMEs) on 345 hepatitis B prevention. The CMEs helps healthcare providers to maintain, develop, or increase 346 the knowledge and skills about the provision of healthcare. This is a considerably low 347 proportion given the public health importance of hepatitis B. The low proportion of HCFs 348 349 holding CMEs may have resulted from the fact that less than a third of the HCF had a healthcare provider trained in the management of hepatitis B, despite more than three quarters being 350 trained in hepatitis B testing. The fact that only a few HCFs had healthcare providers trained 351 in hepatitis B management indicates a knowledge gap among healthcare providers in HCFs in 352 Wakiso district. Therefore, our study recommends the need to train healthcare providers, 353 particularly those in health centre IIIs and public HCFs, irrespective of the location of HCF. 354

#### 355 Conclusions

Our study revealed an uneven distribution of hepatitis B services. The majority of the hepatitis B services were clustered around major towns, municipalities, and Kampala City, with just a few sparsely located in rural areas. Regarding the availability of hepatitis B prevention services,

359	less than a third of the HCFs had hepatitis B vaccine doses in stock in the last 12 months, less
360	than a third had a routine vaccination schedule for the health care providers while sightly more
361	than half offered hepatitis B testing services. The proportion of HCFs offering hepatitis B
362	services was higher among urban HCFs, private HCFs, and hospitals. This calls a extension of
363	hepatitis B prevention services to rural, public and PNFP healthcare facilities.
364	Declarations
365	Consent for publication: Not Applicable
366	Availability of data and material
367	All relevant data are within the paper and its Supporting Information files.
368	Competing interests
369	The authors declare that they have no competing interests.
370	Funding
371	No funding source to declare.
372	Authors' contributions
373	TS, JBI and RKM were involved in the conceptualisation of the study, design, data analysis,
374	and drafting of the manuscript. AN STW, RN, ND, MN, JN, WKK and JNB participated in
375	data analysis, interpretation of findings and drafting of the manuscript. All authors read and
376	approved the final manuscript. JBI drew the maps presented in the manuscript.
377	Acknowledgements

We thank the Wakiso District Health office for granting the study team administrative clearance during the survey. Our sincere thanks also go to the management/administration of the different healthcare facilities, without whom, this study would not have been accomplished.

- Finally, we appreciate the research assistants for their role in undertaking the survey from
- 382 which the current manuscript has been written.

383

# 384 **References**

1. WHO. Global hepatitis report 2017: World Health Organization; 2017.

Le MH, Yeo YH, So S, Gane E, Cheung RC, Nguyen MH. Prevalence of hepatitis B vaccination
 coverage and serologic evidence of immunity among US-born children and adolescents from 1999 to
 JAMA network open. 2020;3(11):e2022388-e.

389 3. MoH MoH. Uganda population-based HIV impact assessment (UPHIA) 2016-2017.
 390 Kampala2017.

3914.WHO. Guidelines on hepatitis B and C testing: policy brief. World Health Organization; 2016.

WHO. WHO Guidelines on Hepatitis B and C Testing. Geneva: World Health Organization;
 2017. Licence: CC BY-NC-SA 3.0 IGO. 2018.

Ray G. Current scenario of hepatitis B and its treatment in India. Journal of clinical and
 translational hepatology. 2017;5(3):277.

WHO. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral
 hepatitis. World Health Organization; 2016.

8. Negro F. Hepatitis D virus coinfection and superinfection. Cold Spring Harbor perspectives in
 medicine. 2014;4(11):a021550.

400 9. Akande KO, Fowotade A, Adekanmbi O. The effect of Hepatitis D co-infection on the
401 immunologic and molecular profile of Hepatitis B in asymptomatic Chronic Hepatitis B patients in
402 southwest Nigeria. Journal of Immunoassay and Immunochemistry. 2020;41(3):272-80.

- Hung M, Williams W, Lu P, Woods L, Koppaka R, Lindley M. Vaccination coverage among
  adults in the United States, national health interview survey, 2017. Centers for Disease Control and
  Prevention. 2018.
- Ssekamatte T, Mukama T, Kibira SP, Ndejjo R, Bukenya JN, Kimoga ZPA, et al. Hepatitis B
  screening and vaccination status of healthcare providers in Wakiso district, Uganda. PLoS One.
  2020;15(7):e0235470.

409 12. Ocan M, Acheng F, Otike C, Beinomugisha J, Katete D, Obua C. Antibody levels and
410 protection after Hepatitis B vaccine in adult vaccinated healthcare workers in northern Uganda. Plos
411 one. 2022;17(1):e0262126.

Awoke N, Mulgeta H, Lolaso T, Tekalign T, Samuel S, Obsa MS, et al. Full-dose hepatitis B
virus vaccination coverage and associated factors among health care workers in Ethiopia: A
systematic review and meta-analysis. PLoS One. 2020;15(10):e0241226.

- 415 14. Aaron D, Nagu TJ, Rwegasha J, Komba E. Hepatitis B vaccination coverage among healthcare
  416 workers at national hospital in Tanzania: how much, who and why? BMC infectious diseases.
  417 2017;17(1):1-7.
- 418 15. Sonderup MW, Spearman CW. Global Disparities in Hepatitis B Elimination—A Focus on
  419 Africa. Viruses. 2022;14(1):82.

420 16. Press statement by the Minister of Health of the Republic of Uganda [press release].421 Kampala2016.

422 17. Bwogi J, Braka F, Makumbi I, Mishra V, Bakamutumaho B, Nanyunja M, et al. Hepatitis B

423 infection is highly endemic in Uganda: findings from a national serosurvey. African health sciences.424 2009;9(2).

- 425 18. UBOS. The National Population and Housing Census 2014 Area
- 426 Specific Profile Series, Kampala, Uganda. 2017 [Available from: <u>https://www.ubos.org/wp-</u>
   427 content/uploads/publications/2014CensusProfiles/WAKISO.pdf.
- 428 19. Ministry of Health. National health facility master facility list 2018 Kampala, Uganda:
- 429 Ministry of Health; 2018 [cited 2021 2021]. Available from:

430 <u>http://library.health.go.ug/publications/health-facility-inventory/national-health-facility-master-</u>

431 <u>facility-list-2018</u>.

- 432 20. Ministry of Health. Guidelines on establishment of health sub-districts management
- 433 committee Kampala, Uganda: Ministry of Health; 2010 [cited 2021 14-06-2021]. Available from:

434	http://library.health.go.ug/publications/health-centres-iv-iii-and-ii/guidelines-establishment-health-
435	sub-districts-management.
436 437	21. Wang S, Smith H, Peng Z, Xu B, Wang W. Increasing coverage of hepatitis B vaccination in China: a systematic review of interventions and implementation experiences. Medicine. 2016;95(19).
438 439	22. Malewezi B, Omer SB, Mwagomba B, Araru T. Protecting health workers from nosocomial Hepatitis B infections: A review of strategies and challenges for implementation of Hepatitis B
440	vaccination among health workers in Sub-Saharan Africa. Journal of epidemiology and global health.
441	2016;6(4):229-41.
442	23. WHO. Service availability and readiness assessment (SARA): an annual monitoring system for
443	service delivery: reference manual. World Health Organization; 2013.
444	24. Data for Impact. Service Availability and Readiness Assessment (SARA) 2021 [cited 2021 14-
444	06-2021]. Available from: https://www.data4impactproject.org/prh/service-delivery/access-to-
443 446	sexual-and-reproductive-health-services/service-availability-and-readiness-assessment-sara/.
447	25. Ministry of Health. Uganda Services Availability and Readiness Assessment 2013. Summary
448	Report:Key findings in figures Kampala, Uganda: Ministry of Health; 2013 [Available from:
449	http://library.health.go.ug/publications/quality-assurance-quality-improvement/uganda-services-
450	availability-and-readiness.
451 452	26. Government of Uganda. THE PHYSICAL PLANNING ACT, 2010. Kampala, Uganda2020 [Available from: https://www.kcca.go.ug/uploads/acts/Physical Planning Act 2010.pdf.
452	
453	
454 455	attitude among primary healthcare providers predicts better hepatitis B prevention practices:
455	evidence from a cross-sectional survey in Wakiso district, Central Uganda. Health Psychology and
456	Behavioral Medicine. 2021;9(1):298-314.
457	28. Ssekamatte T, Mukama T, Kibira SPS, Ndejjo R, Bukenya JN, Kimoga ZPA, et al. Hepatitis B
458	screening and vaccination status of healthcare providers in Wakiso district, Uganda. PLOS ONE.
459	2020;15(7):e0235470.
460	29. Okurut FN, Odwee JJ, Adebua A. Determinants of regional poverty in Uganda. 2002.
461	30. World bank. The Uganda Poverty Assessment Report 2016. Farms, cities and good fortune:
462	Assessing poverty reduction in Uganda from 2006 to 2013. 2016.
463	31. Ministry of Health. Uganda Population-based HIV Impact Assessment (UPHIA) 2016-2017:
464	Final
465	Report. Kampala: Ministry of Health 2019 [Available from: <u>https://phia.icap.columbia.edu/wp-</u>
466	content/uploads/2019/07/UPHIA Final Report Revise 07.11.2019 Final for-web.pdf.
467	32. Ministry of Health. UGANDA COMMENDED FOR EFFORTS IN THE FIGHT AGAINST HEPATITIS
468	B. Kampala: Ministry of Health; 2018 [Available from:
469	https://www.health.go.ug/2019/12/02/uganda-commended-for-efforts-in-the-fight-against-
470	hepatitis-b/.
471	33. Boulding KE. The concept of need for health services. The Milbank Memorial Fund Quarterly.
472	1966;44(4):202-23.
473	34. Tetui M, Ssekamatte T, Akilimali P, Sirike J, Fonseca-Rodríguez O, Atuyambe L, et al.
474	Geospatial Distribution of Family Planning Services in Kira Municipality, Wakiso District, Uganda.
475	Frontiers in Global Women's Health. 2021;1(28).
476	35. Mordasini M. Implementing Global Public Policies: Are the Aid Agencies Walking the Talk?
477	International Development Policy   Revue internationale de politique de développement. 2012(3).